Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Cerevance, a private, UK headquartered clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the appointment of Craig Thompson as chief executive (CEO). 20 April 2022
Biotech funder and incubator Flagship Pioneering today announced that Michael Severino is joining the company as chief executive (CEO)-partner. 13 April 2022
Swiss rare diseases specialist Santhera Pharmaceuticals has appointed Shabir Hasham as chief medical officer (CMO) and a member of its executive management team, effective May 1. 13 April 2022
Danish CNS specialist Lundbeck said on Friday it has has appointed Joerg Hornstein as chief financial officer (CFO) and member of its executive management. He will assume the role no later than September 1, 2022, and he will be registered with the Danish Business Authority. 11 April 2022
UK endocrine diseases specialist Diurnal Group today announced that, following 14 years with the company, Martin Whitaker has decided to step down as chief executive (CEO) and a member of the board of Diurnal, with immediate effect, to enable him to pursue other business opportunities. 4 April 2022
California-based biotech Eikon Therapeutics announced the appointment of Kenneth Frazier as an independent director effective April 1, 2022. 1 April 2022
Alector, a Californian company pursuing an immunological approach to targeting neurological conditions, has appointed a new chief medical officer. 30 March 2022
Californian gene specialist Mammoth Biosciences, a three-year old biotech focused on developing CRISPR products, has made a new senior executive appointment. 24 March 2022
Arenaviral immunotherapies company Hookipa Pharma has announced that Klaus Orlinger has been promoted to the role of chief scientific officer (CSO). 23 March 2022
US pharma giant Merck & Co today announced today that Dr Roy Baynes, head of global clinical development (GCD) and chief medical officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. 23 March 2022
Metagenomi, a California, USA-based genetic medicines company with a versatile portfolio of next-generation gene editing tools, today announced the appointment of Christine Foster, as chief business officer and Alan Cohen, as chief medical officer and senior vice president of Monogenic Diseases. 15 March 2022
Privately-held US biotech Teon Therapeutics has announced the appointment of Serge Messerlian as chief executive and member of the board of directors. 9 March 2022
California, USA-based clinical-stage biotech CODA Biotherapeutics, which is focussed on neurological disorders, has appointed Susan Catalano as chief scientific officer. 9 March 2022
UK and USA-based clinical-stage biopharmaceutical company F-star Therapeutics has appointed James Sandy as chief development officer (CDO), effective March 1. 2 March 2022
Spark Therapeutics, fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease that was acquired by Swiss pharma giant Roche (ROG: SIX) in a $4.8 billion deal in 2020, today announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey Marrazzo as chief executive. 23 February 2022
The end of an era is approaching at Anglo-Swedish drugmaker AstraZeneca as Leif Johansson, non-executive chairman of the board, confirmed that he will be retiring in 2023. 23 February 2022
US cancer therapies specialist Karyopharm Therapeutics saw its shares drop as much as 31% Tuesday, on the news that its chief medical officer was stepping down, even though it also announced two prominent research appointments. 23 February 2022